Construction begins on Novartis’ RLT centre in Texas, US

Novartis has begun construction on its new 46,000ft² RLT manufacturing facility in Denton, Texas, marking the latest step in its $23bn investment in US manufacturing and research. The site is expected to be operational in 2028, adding new roles in advanced manufacturing and bioengineering. Novartis advances RLTs for multiple cancers, supported by a global network of production and supply chain capabilities. Credit: Taljat David / Shutterstock.com. Novartis has begun construction on its new 46,000ft² radioligand therapy (RLT) manufacturing facility in Denton, Texas, marking the latest step in its $23bn investment in US manufacturing and research. The location will serve as…

Source: Pharmaceutical Technology